- Coalesced over 40 different stakeholders in the pediatric and rare liver diseases fields through the Pediatric and Rare Liver Diseases Council and led work groups in research, education, policy, and ICD coding.- Headed the Primary Biliary Cholangitis Patient-Focused Drug Development meeting in alignment with the U.S. FDA, collecting and analyzing valuable patient data to drive and direct drug development.- Planned and executed webinars with topics ranging from children’s story times to congressional briefings.- Acted as a liaison between GLI and both the US and global patient advocacy organizations, biotechnological and pharmaceutical companies, clinicians, researchers, and other stakeholders.- Set the pediatric and rare liver disease policy agenda and kept up-to-date with congressional bills.- Managed the entire pediatric and rare liver disease portfolio, spanning 100+ diseases.- Advised pharmaceutical and biotechnology companies throughout clinical trials, including protocols. - Mentored pediatric and rare liver disease patient organizations and charities across the world.

- Acted as a liaison between Hogg Therapy Associates and payers, parents/guardians, and pediatricians.- Managed all communications, including paperwork, related to obtaining service prior authorizations.- Reviewed and corrected all current accounts to ensure everyone had updated insurance approval.

- Taught English language arts to 150+ students from a diverse range of backgrounds. and cultures.- Fostered an environment of collaboration, progress, understanding, accessibility, and development.- Created and supervised extracurricular activities such as writing club and environmentalism club.

- Launched Kentucky Journal for Undergraduate Scholarship, the first undergraduate research journal in Kentucky.- Served on a steering committee to develop a groundbreaking hybrid academic course combining a non credit-bearing developmental English course with a credit-bearing entry-level English course.